

ERNDIM Administration Office

Manchester Centre for Genomic Medicine 6th Floor, St Mary's Hospital, Oxford Road, Manchester M13 9WL, United Kingdom. **Tel:** +44 161 276 6741 **Fax:** +44 161 850 1145 **Email:** <u>admin@erndim.org</u>

Lysosomal Enzymes in fibroblasts

Scientific Advisor Dr Kees Schoonderwoerd Erasmus MC University Medical Center, P.O. Box 2040 3000 CA Rotterdam Netherlands Email: <u>g.schoonderwoerd@erasmusmc.nl</u> Scheme Organiser Dr. C.W. Weykamp Queen Beatrix Hospital MCA Laboratory P.O. Box 9005 NL – 7100 GG Winterswijk Netherlands Email: c.w.weykamp@skbwinterswijk.nl

Annual Report 2016 Date of issue: 05 April 2017

1. Scheme Design

The scheme has been designed, planned and coordinated by Dr Kees Schoonderwoerd as Scientific Advisor and Dr Cas Weykamp as Scheme Organiser (sub-contractor on behalf of SKML); both appointed by and according to procedures laid down by the ERNDIM Board.

2. Samples

All EQA materials are lyophilised samples of human fibroblasts. All samples were obtained following local ethical and consent guidelines.

Sample	Disorder	Enzyme defect					
LF1	GM1	beta-Galactosidase					
LF2	Fabry	Alpha-Galactosidase					
LF3	Sandhoff	Beta-Hexosaminidase A+B					
LF4	Hurler	alpha-iduronidase					
LF5	Gaucher	beta-Glucosidase					
LF6	Sandhoff	Beta-Hexosaminidase A+B					

Table 1: Samples for the 2016 scheme

3. Shipment

One shipment of 6 samples was sent out on the 9th February 2016, to the 75 laboratories, from 30 countries, which registered for the scheme.

4. Receipt of results

There were three submission deadlines from April to October 2016, two before the summer holiday and one after the summer holiday. Laboratories were asked to submit results for each EQA sample by the relevant submission deadline using the results website <u>www.erndimga.nl</u>.

Laboratories were asked to report the total protein and the activities for 10 enzymes in absolute units and as a percentage of their own laboratories control, see Table 2 for details. Laboratories could submit results for as many, or as few, of these 10 enzymes as they wished. Laboratories were also asked to select an 'interpretation' of the results from a dropdown list on the results website.

Table 2: Analytes to be measured

Analyte	Parameter 1	Parameter 2
Protein	mg/vial	
beta-Hexosaminidase A+B	37 degr; nmol/7h/mg	37 degr; % mean control
alpha-Galactosidase	nmol/h/mg	% mean control
beta-Galactosidase	nmol/h/mg	% mean control
alpha-Glucosidase	nmol/h/mg	% mean control
beta-Glucosidase	nmol/h/mg	% mean control
beta-Hexosaminidase A	nmol/h/mg	% mean control
alpha-Iduronidase	nmol/h/mg	% mean control
Galactosamine-6-sulphate sulphatase	nmol/17h/mg	% mean control
Galactosylceramidase	nmol/17h/mg	% mean control
Sphingomyelinase	nmol/h/mg	% mean control

5. Scoring scheme

For each enzyme 2 criteria were scored: 1) diagnosis and 2) coefficient of variation (CV). A maximum of 2 points was awarded for each criterion. For the protein value a maximum of 2 points could be scored.

	Criteria		Score
Protein		CV<35%	2
	cv	CV=35 or 35% <cv<60%< td=""><td>1</td></cv<60%<>	1
		CV>60%	0
Enzymes		Diagnosis correct	2
	Diagnosis	Diagnosis partially correct	1
		Diagnosis incorrect	0
		CV<35%	2
	cv	CV=35 or 35% <cv<60%< td=""><td>1</td></cv<60%<>	1
		CV>60%	0

 Table 3: Scoring criteria

The maximum possible score for the scheme was 42 points (10 enzymes plus the protein value). Laboratories that participated fully in the scheme (i.e. submitted enough results for their performance to be assessed) but scored less than 60% of their maximum possible score were considered to be unsatisfactory performers in the scheme. For example, if a laboratory submitted results for 8 analytes (protein & 7 enzymes) their maximum possible score would be 30 points so they would need to score 18 or more points to be a satisfactory performer. If 60% of a laboratory's maximum possible score was not a full integer the number of points for satisfactory performance was rounded down to the next full integer.

5.1. Diagnosis

The participants must select an interpretation from the dropdown list on the results website.

Diagnosis correct indicates correct interpretation and correct measurement of enzyme activity level. In cases of control enzyme activity, the activity should be >15% of the mean control while in case of a patient enzyme activity, the activity should be <30% of the mean control.

Diagnosis partially correct indicates incorrect interpretation and correct enzyme activity level or correct interpretation and incorrect enzyme activity level.

Diagnosis incorrect indicates incorrect interpretation and incorrect enzyme activity level.

5.2. Coefficient of variation

Results submitted for samples LF3 and LF 6 were used to calculate the coefficient of variation (CV) according to the following formula.

CV = Activity LF6-activity LF3/mean

With only two samples (LF3 and LF6) it was not possible to calculate the standard deviation.

6. Results

Seventy-one laboratories (94.6% of registered laboratories) submitted sufficient results for their performance to be assessed. One laboratory (1.3%) did not submit any results and three laboratories (4%) did not submit enough results for their performance to be assessed.

Full details of each participant's results are given in Appendix 1 but summaries are presented here:

- Over 69% of all laboratories submitted results for 7 or more enzymes, see Table 4.
- The proficiency per analyte is given in Table 5.
- Table 6 shows the percentage of the maximum possible score for the laboratories that submitted results.
- 63 laboratories that submitted results scored 60% or more of their maximum possible score and were classed as satisfactory performers.

Table 4: Number of enzymes for which laboratories

 submitted results (excluding non- and partial submitters)

Number of Enzymes for which results were submitted	Number of laboratories
0	0
1	3
2	2
3	0
4	5
5	4
6	6
7	4
8	8
9	11
10	28
Total number of labs	71

Analyte	No of retur
Table 5: Proficiency per analyte	

Analyte	No of returns	Diagnosis (% ¹)	CV (% ¹)	Total Proficiency (% ¹)
Protein	74	n.a.	87	87
β-Hexosaminidase A+B	63	94	71	82
α-Galactosidase	68	83	80	82
β-Galactosidase	69	94	81	87
α-Glucosidase	52	80	72	76
β-Glucosidase	67	92	81	86
β-Hexosaminidase A	59	90	83	86
α-lduronidase	57	96	81	88
Galactosamine-6-sulphate sulphatase	42	99	66	82
Galactocerebrosidase	48	96	70	83
Sphingomyelinase	45	99	69	84

¹= percentage of maximum possible score (for laboratories that submitted results)

Table 6: Percentage of maximum possible scores for laboratories that submitted results (excluding partial submitters)

%age of maximum possible score	No of submitting labs	%age of submitting labs
0% – 9%	0	0%
10% – 19%	0	0%
20% – 29%	0	0%
30% –39%	0	0%
40% – 49%	2	2.8%
50% –59%	6	8.5%
60% –69%	0	0%
70% –79%	11	15.5%
80% –89%	20	28.2%
90% –99%	21	29.6%
100%	11	15.5%
Totals	71	100%



	No of enzymes for which:						
Lab No	results were submitted by lab	lab had satisfactory performance					
1	10	10					
2	8	8					
3	10	9					
4	9	0 (partial submitter)					
5	10	9					
6	9	9					
7	7	7					
8	10	10					
9	10	6					
10	4	3					
11	10	5					
12	9	7					
13	4	0 (partial submitter)					
14	10	7					
15	10	8					
16	8	8					
17	10	10					
18	10	10					
19	10	5					
20	8	8					
21	6	6					
22	7	4					
23	5	1					
24	9	6					
25	9	8					
26	10	10					
27	5	5					
28	10	9					
29	8	8					
30	10	9					
31	7	7					
32	10	8					
33	8	7					
34	6	6					
35	10	10					
36	10	9					
37	1	1					

	No of enzymes for which:								
Lab No	results were submitted by lab	lab had satisfactory performance							
38	6	1							
39	1	1							
40	10	9							
41	7	7							
42	2	1							
43	4	3							
44	5	4							
45	6	6							
46	8	3							
47	8	5							
48	9	9							
49	6	2							
50	10	9							
51	9	7							
52	10	9							
53	10	8							
54	0	0 (non-submitter)							
55	9	5							
56	9	9							
57	10	8							
58	4	4							
59	4	3							
60	10	7							
61	10	9							
62	10	7							
63	8	7							
64	2	2							
65	9	1							
66	10	8							
67	8	8							
68	4	3							
69	6	1							
70	1	1							
71	4	0 (partial submitter)							
72	10	7							
73	10	8							
74	5	5							
75	9	3							

7. Comments here on overall scheme performance

Overall all samples were correctly interpreted, only for the enzymes α -Galactosidase(Fabry) and α -Glucosidase the % of maximal possible score was below 90%. For the sample of the Fabry patient(LF2) about 9% of the participants both the interpretation and the amount of enzyme activity measured was not correct. In sample LF4(Hurler patient) about 25% of the participants measured an enzyme activity of α -Glucosidase on the level of Pompe patient.

8. Comparison to previous years

In 2016 and 2015 arylsulfatase and iduronate-2-sulphate sulphatase activity measurements were not in the scheme, therefore no comparison can be made. For most enzymes there was no difference in the CV between 2014, 2015 and 2016 however there was a remarkable increase in the number of participants with CV>35 for the analytes α -Galactosidase α -Glucosidase and galactocerebrosidase in 2016.

2014					2015				2016			
%age of labs with:				%a	%age of labs with:			%age of labs with:				
Analyte	No data	CV <35	CV >35	No of labs	No data	CV <35	CV >35	No of labs	No data	CV <35	CV >35	No of labs
Protein/vial	7%	83%	10%	71	10%	80%	10%	71	5%	84%	11%	74
Arylsulfatase A	14%	63%	23%	56	-	-	-	-	-	-	-	-
α-Galactosidase	8%	73%	19%	64	11%	66%	23%	62	10%	57%	32%	68
β-Galactosidase	12%	63%	25%	69	11%	64%	26%	66	6%	73%	22%	69
α-Glucosidase	8%	68%	24%	49	10%	63%	27%	48	10%	46%	44%	52
β-Glucosidase	11%	70%	19%	64	14%	67%	19%	63	9%	70%	21%	67
β-Hexosaminidase A	13%	66%	21%	62	15%	72%	13%	60	7%	70%	24%	59
β-Hexosaminidase A+B	-	-	-	-	12%	60%	28%	60	6%	59%	35%	63
α-Iduronidase	4%	76%	20%	54	13%	69%	19%	54	7%	70%	23%	57
Iduronate-2-sulphate sulphatase	10%	61%	29%	43	-	-	-	-	-	-	-	-
Galactosamine-6- sulphate sulphatase	-	-	-	-	15%	59%	27%	41	12%	60%	29%	42
Galactocerebrosidase	7%	65%	28%	46	13%	63%	24%	46	10%	52%	38%	48
Sphingomyelinase	9%	59%	17%	46	16%	71%	14%	44	9%	64%	27%	45

Table 8: Comparison between CV data from 2014, 2015 and 2016

Kees Schoonderwoerd Scientific advisor Cas Weykamp Scheme Organiser

Appendix 1 (part 1): Results per laboratory (see page 8 for key)

	Protein	/vial	B-Hexos	saminid	lase A+B	α-Ga	alactos	idase	β-0	Galacto	sidase	
-		Score			Score			Score	CV			
Lab No	CV	CV	CV	CV	Diagnosis	CV	CV	Diagnosis		CV	Diagnosis	
1	0	2	12	2	2	3	2	2	3	2	2	
2	25	2	22	2	2	3	2	2	10	2	2	
3	23	2	15	2	2	10;d-	2	1	66	0	2	
4	R0	0	R0	0	2	R0	0	2	R0	0	2	
5	17	2	200	0	2	7	2	2	13	2	2	
6	8	2	33	2	2	9	2	2	1	2	2	
7	1	2	8	2	2	10	2	2	5	2	2	
8	6	2	0	2	2	16	2	2	31	2	2	
9	10	2	128	0	2	R0	0	2	78	0	2	
10	22	2	16	2	2				30	2	2	
11	6	2	R0;D0	0	2	21	2	2	5	2	2	
12	6	2	22	2	2	12	2	2	14	2	2	
13	R0	0	R0;D0	0	0	200;D+	0	1			-	
14	10	2	59	1	2	10	2	2	56	1	2	
15	1	2	160	0	2	8	2	2	30	2	2	
16	4	2	13	2	2	2	2	2	4	2	2	
17	4	2	17	2	2	11	2	2	2	2	2	
18	9	2	2	2	2	4	2	2	0	2	2	
19	5	2	77	0	2	4;d-D-	2	0	90	0	2	
20	0	2	36	1	2	40			8	2	2	
21	8	2	10	2	2	12	2	2	0	2	2	
22	11	2	18	2	2	3;D-d-	2	0	5;D-d-	2	0	
23 24	0 4	2	147 139	0	2	35;D- 9;d-D-	1 2	1 0	73;D- 7	0 2	1 2	
24	3	2	9	2	2	19 19	2	2	7	2	2	
25	39	1	9 19	2	2	2	2	2	8	2	2	
20	9	2	19	2	2	۷.	2	2	29	2	2	
28	34	2	7	2	2	0	2	2	1	2	2	
29	2	2	3	2	2	0	2	2	6	2	2	
30	8	2	17	2	2	15	2	2	8	2	2	
31	1	2	2	2	2	2	2	2	1	2	2	
32	42	1	65	0	2	46	1	2	34	2	2	
33	3	2	46	1	2	54	1	2	45	1	2	
34	38	1	1	2	2	3	2	2	6	2	2	
35	12	2	17	2	2	15	2	2	3	2	2	
36	11	2	26	2	2	15	2	2	13	2	2	
37	67	0				15D+D0	2	1				
38	62	0				R0	0	2	R0	0	2	
39	6	2										
40	12	2	1	2	2	1	2	2	13	2	2	
41	16	2	39	1	2	20;D-	2	1	16	2	2	
42	4	2				19;d-D-	2	0	20	2	2	
43	6	2	1;2D-	2	0				0	2	2	
44	20	2	27	2	2	32;D-d-	2	0	24;D-	2	1	
45	40	1				28	2	2	34	2	2	
46	192	0	4	2	2	R0	0	2	8	2	2	



Lysosomal Enzymes in fibroblasts Scheme Annual Report 2016 (issued: 05 April 2017)



	Protein	B-Hexos	saminic	lase A+B	α-Ga	alactos	idase	β-0	β-Galactosidase			
		Score			Score		Score		CV		Score	
Lab No	CV	CV	CV	CV	Diagnosis	CV	CV	Diagnosis		CV	Diagnosis	
47	11	2	9	2	2	2;D-d-	2	0	1	2	2	
48	9	2	21	2	2	14	2	2	2	2	2	
49	15	2	18;D-	2	1	46;D0	1	1	28	2	2	
50	2	2	14	2	2	14	2	2	14	2	2	
51	6	2	21	2	2	11	2	2	22	2	2	
52	18	2	14	2	2	18;D-	2	1	5	2	2	
53	11	1	5	2	2	14	2	2	21	2	2	
54	nd		nd			nd			nd			
55	9	2	84	0	2	103	0	2	79	0	2	
56	4	2	16	2	2	1	2	2	9	2	2	
57	9	2	18	2	2	124	0	2	21	2	2	
58	8	2				0	2	2				
59	3	2	4;2D-	2	0	15;D-	2	1	5;d-	2	1	
60	26	2	200	0	2	29	2	2	81;2d+	0	0	
61	16	2	3	2	2	24	2	2	10	2	2	
62	12	2	1	2	2	59	1	2	24	2	2	
63	8	2	54	1	2	18	2	2	13	2	2	
64	2	2							1;D-	2	1	
65	R0	0	R0;D0	0	2	R0	0	2	R0	0	2	
66	16	2	64	0	2	19	2	2	27	2	2	
67	6	2	21	2	2	2	2	2	1	2	2	
68	24	2	47	1	2	9	2	2	28	2	2	
69	27	2				R0;D0	0	1	33	2	2	
70	10	2				1;D0	2	1	nd			
71	R0	0				R0;D0;D+	0	1	R0;D0	0	1	
72	3	2	57	1	2	29	2	2	53	1	2	
73	12	2	90	0	2	43	1	2	60	0	2	
74	11	2	7;D-	2	1	2	2	2	16	2	2	
75	44	1	11	2	2	54	1	2	36	1	2	

<u>Key</u>

green cells = correct CV (<35), correct interpretation and correct enzyme level **red cells** =Incorrect measurement, CV (>35) or incorrect interpretation or enzyme level

blue cells =not all samples measured

d- = enzyme activity patient sample > 30% control Fibroblast

d+ = enzyme activity other samples < 20 % control Fibroblasts

D- = patient sample not indicated as patient in drop down list

D+ = sample falsely indicated as patient sample in drop down list

D0 = patient sample not measured

R0 = CV calculation not possible as one or both of LF3 and LF6 (duplicate samples) were not measured

nd = not detected (i.e. result not submitted)

Appendix 1 (part 2): Results per laboratory (see page 8 for key)

	α-G	lucos	idase	β-G	lucos	idase	β-Hex	osam	inidase A	α-Iduronidase		
	Score					Score	Score			Score		
Lab No	CV	CV	Diagnosis	CV	CV	Diagnosis	CV	CV	Diagnosis	CV	CV	Diagnosis
1	4	2	2	10	2	2	6	2	2	6	2	2
2	19;2d+	2	1	5	2	2	20	2	2	7	2	2
3	7	2	2	47	1	2	5	2	2	35	1	2
4	R0	0	2	R0	0	2	R0	0	2	R0;D0	0	2
5	11;2d+	2	1	43	1	2	28	2	2	21	2	2
6	12	2	2	1	2	2	11;D+	2	1	3	2	2
7	8;2d+	2	1	8	2	2	18	2	2	3	2	2
8	5;d+	2	1	1	2	2	26	2	2	0	2	2
9	3	2	2	56	1	2	29	2	2	19	2	2
10				29	2	2	90:D+	0	1			
11	7;D+d+	2	0	12	2	2	R0	0	2	25;D0	2	0
12	80	0	2	4	2	2	62	0	2	8	2	2
13				R0;d-D-	0	0						
14	126	0	2	0	2	2	43	1	2	38	1	2
15	6;2d+	2	1	38	1	2	8	2	2	7	2	2
16	2;D+	2	1	7	2	2	4	2	2			
17	6	2	2	0	2	2	4	2	2	5	2	2
18	3	2	2	3	2	2	5	2	2	8	2	2
19	21;d+D+	2	0	9	2	2	0;D+d+	2	0	5	2	2
20				29	2	2	3	2	2	22	2	2
21				1	2	2	8	2	2	11	2	2
22				5	2	2	54;D+	1	1	44	1	2
23				113;D-	0	1	14	2	2			
24				8	2	2	7	2	2	135	0	2
25	55;d+	1	1	2	2	2	21	2	2	29	2	2
26	6	2	2	14:D-	2	1	0	2	2	13	2	2
27				1	2	2				10	2	2
28	41;d+	1	1	3	2	2	0	2	2	15	2	2
29	4	2	2	4	2	2				10	2	2
30	77;d+	0	1	19	2	2	37	1	2	6	2	2
31	4	2	2	2	2	2	1					
32	24	2	2	30	2	2	31	2	2	19	2	2
33	42;2d+	1	1	57	1	2	30	2	2	36	1	2
34				10	2	2	1	2	2			
35	3	2	2	5	2	2	14	2	2	9	2	2
36	5	2	2	5	2	2	12	2	2	6	2	2
37												
38	R0	0	2	R0;D0	0	2				R0	0	2
39										8	2	2
40	12;d+	2	1	3	2	2	4	2	2	25	2	2
41	24	2	2	24	2	2	4	2	2	43	1	2
42												
43							7	2	2			
44				9	2	2	25:D+	2	1			
45	36	1	2	17:D-	2	1	29	2	2	17;D-	2	1
46	R0;d+D+	0	0	88;D-d+	0	0	23	2	2	109	0	2



Lysosomal Enzymes in fibroblasts Scheme Annual Report 2016 (issued: 05 April 2017)



	α-Glucosidase			β-G	lucos	idase	β-Hex	osam	inidase A	α-I	duron	idase
			Score			Score		Score				Score
Lab No	CV	CV	Diagnosis	CV	CV	Diagnosis	CV	CV	Diagnosis	CV	CV	Diagnosis
47				1	2	2	11	2	2	3	2	2
48	15	2	2	9;d-	2	1	11	2	2	15	2	2
49	92;D+	0	1	160;D-	0	1						
50	5	2	2	22	2	2	10	2	2	11	2	2
51	117	0	2	47	1	2	24	2	2	86	0	2
52	11	2	2	4	2	2	8	2	2	9	2	2
53	144	0	2	4	2	2	6	2	2	26	2	2
54	nd			nd			nd			nd		
55	4	2	2	12	2	2	37	1	2	55	1	2
56	4	2	2	6	2	2	2	2	2	9	2	2
57	36	1	2	32	2	2	22	2	2	32	2	2
58	11	2	2	5	2	2				0	2	2
59							30	2	2			
60	16;d+	2	1	0	2	2	10;D+	2	1	2	2	2
61	15	2	2	3	2	2	24	2	2	6	2	2
62	21;d+D+	2	0	33	2	2	39;D+	1	1	1	2	2
63	32	2	2	34	2	2	13	2	2	31	2	2
64				7	2	2						
65	R0	0	2	R0	0	2	R0	0	2	R0;D0	0	2
66	4	2	2	3	2	2	17	2	2	26	2	2
67	16	2	2	7	2	2				5	2	2
68							48:2D+	1	0			
69				R0	0	2				R0;D0	0	1
70												
71	R0	0	2	R0;D0D+	0	1						
72	62	0	2	2	2	2	60	0	2	14	2	2
73	8	2	2	9	2	2	1	2	2	15;D0	2	1
74				22;D-	2	1	0;D+	2	1			
75				60	0	2	R0	0	1	131	0	2

Appendix 1 (part 3): Results per laboratory (see page 8 for key)

		samine sulpha		Galac	ctocer	ebrosidase	Sphingomyelinase			
			Score			Score		Score		
Lab No	CV	CV	Diagnosis	CV	CV	Diagnosis	CV	CV	Diagnosis	
1	3	2	2	0	2	2	1	2	2	
2	19	2	2							
3	15	2	2	0	2	2	52	1	2	
4				R0	0	2	R0	0	2	
5	16	2	2	42	1	2	5	2	2	
6				15	2	2	22	2	2	
7										
8	10	2	2	0	2	2	23	2	2	
9	51	1	2	10	2	2	71	0	2	
10										
11	R0	0	2	9	2	2	1	2	2	
12	40	1	2				8	2	2	
13				R0	0	2				
14	R0	0	2	49	1	2	R0;d+	0	1	
15	83	0	2	0	2	2	40	1	2	
16				1	2	2	1	2	2	
17	1	2	2	11	2	2	4	2	2	
18	2	2	2	0	2	2	1	2	2	
19	22	2	2	55	1	2	42	1	2	
20	50	1	2	9;d+	2	1	12	2	2	
21										
22				45	1	2				
23										
24	31	2	2	5	2	2	6	2	2	
25	5	2	2	22	2	2		_		
26	4	2	2	5	2	2	28	2	2	
27	2	2	2	10;d+	2	1		_	-	
28	0	2	2	12	2	2	7	2	2	
29	9	2	2		_		14	2	2	
30	40	1	2	14;d+	2	1	6	2	2	
31	1	2	2		_		8	2	2	
32	9	2	2	0	2	2	74	0	2	
33	21	2	2	_						
34			<u> </u>	0	2	2	-			
35	3	2	2	1	2	2	5	2	2	
36	113	0	2	42	1	2	27	2	2	
37		0	0							
38	R0	0	2							
39	66	0	2	2	<u></u>	<u> </u>	4	0		
40	66	0	2	3	2	2	1	2	2	
<u>41</u> 42										
42				45	1	n				
43				45	1	2				
44 45										
	D0.41	0	1							
46	R0;d+	0	1							



Lysosomal Enzymes in fibroblasts Scheme Annual Report 2016 (issued: 05 April 2017)

	Galactosamine-6-sulphate sulphatase			Galac	tocer	ebrosidase	Sphingomyelinase				
			Score		Score				Score		
Lab No	CV	CV	Diagnosis	CV	CV	Diagnosis	CV	CV	Diagnosis		
47				66	0	2	62	0	2		
48	19	2	2	15	2	2					
49	140	0	2								
50	12	2	2	72	0	2	22	2	2		
51				3	2	2	46	1	2		
52	1	2	2	82	0	2	22	2	2		
53	9	2	2	91	0	2	14	2	2		
54	nd			nd			nd				
55				57	1	2	94	0	2		
56				4	2	2	5	2	2		
57	158	0	2	5	2	2	33	2	2		
58											
59											
60	41	1	2	4;d+	2	1	63	0	2		
61	8	2	2	61	0	2	13	2	2		
62	13	2	2	32	2	2	105	0	2		
63							63	0	2		
64											
65				R0	0	2	R0	0	2		
66	80	0	2	28	2	2	14	2	2		
67				18	2	2	3	2	2		
68											
69				R0	0	2	R0	0	2		
70											
71											
72	95	0	2	48	1	2	8	2	2		
73	2	2	2	47	1	2	4	2	2		
74											
75	R0	0	2	R0	0	2	70	0	2		

